A Phase II, Randomized, Multicenter Study to Assess the Efficacy of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP): The AGNOSTOS Trial

Trial Profile

A Phase II, Randomized, Multicenter Study to Assess the Efficacy of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP): The AGNOSTOS Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Tumours
  • Focus Therapeutic Use
  • Acronyms AGNOSTOS
  • Most Recent Events

    • 11 Oct 2016 Planned number of patients changed from 120 to 132.
    • 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
    • 20 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top